With restricted target cell types, the application of IFNλ as antiviral agent is expected to has less side-effects than IFNα therapy, for example it is less likely to cause leukopenias that is common in IFNα therapy [12, 15, 16]. The gene discussed is IFNA17; the disease is Decreased total leukocyte count.